# US 2014/0155471 A1 · Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155471 A1
- Document ID: US20140155471A1
- Status: Published application
- Kind: A1
- Application number: 14/131,947
- Filed: 2012-07-12
- Published: 2014-06-05
- Earliest claimed: 2011-07-12
- Assignees: University of Rochester
- Inventors: Kim Tieu; William J. Bowers; Phillip M. Rappold
- Web page: https://patentgrep.com/patent/US20140155471A1

## CPC

- C12N 15/85: for animal cells
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods of treating a neurological disease or injury in a subject comprising administering to the subject a recombinant adeno-associated virus (rAAV) vector comprising a DRP1-encoding nucleic acid, wherein the DRP1 encoded by the nucleic acid comprises a mutation compared to wild-type DRP1.

## Claims

### Claim 1

A method of treating a neurological disease or injury in a subject comprising administering to the subject a recombinant adeno-associated virus (rAAV) vector comprising a DRP1 encoding nucleic acid, wherein the DRP1 encoded by the nucleic acid comprises a mutation compared to wild-type DRP1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurological disease or injury comprises mitochondrial fragmentation, mitochondrial dysfunction or mitochondrial DNA mutation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the neurological disease or injury is selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, stroke, and ischemia.

### Claim 4 (depends on 3)

The method of claim 3, wherein the neurological disease or injury is Parkinson's disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein the vector comprises an AAV compatible plasmid and wherein the plasmid comprises a promoter functionally linked to the DRP1 encoding nucleic acid.

### Claim 6 (depends on 5)

The method of claim 5, wherein the plasmid is a pFBGR plasmid.

### Claim 7 (depends on 5)

The method of claim 5, wherein the promoter is a cytomegalovirus promoter.

### Claim 8 (depends on 1)

The method of claim 1, wherein the vector comprises at least two inverted terminal repeats.

### Claim 9 (depends on 1)

The method of claim 1, wherein the DRP1 mutation is K38A.

### Claim 10 (depends on 1)

The method of any claim 1, wherein the rAAV is selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV 10 and AAV 11.

### Claim 11 (depends on 1)

The method of claim 1, wherein the vector is administered stereotactically into a selected brain region.

### Claim 12 (depends on 11)

The method of claim 11, wherein the selected brain region is the substantia nigra.

### Claim 13 (depends on 11)

The method of claim 11, wherein the selected brain region is the striatum.

### Claim 14 (depends on 11)

The method of claim 11, wherein the selected brain region is the hippocampus.

### Claim 15 (depends on 1)

The method of claim 1, wherein the vector is administered intraventricularly.

### Claim 16 (depends on 1)

The method of claim 1, wherein the vector is administered by lumbar puncture.
